On the other hand, the hyperactivations of Akt and ERK pathways, as a consequence of diverse clinical cancer therapies (chemotherapy, targeted therapy, and radiation therapy), play an important role in drug resistance (Obenauf et al., 2015). Here, AKT1 is linked to cancer.